Clinical trials: Renal Transplant Recipients
Antibody-mediated Rejection
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure.
- Trial name
- TRANSCEND (NCT06685757)
- Testing
- Felzartamab
- Where
- 56 sites in United States, Argentina and 10 more
- Volunteers
- 132 people
- Sponsor
- Biogen
Transplantation, Kidney
VEL-101 to Prevent Rejection After Kidney Transplantation
This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.
- Trial name
- RENGEVITY-201 (NCT07290777)
- Testing
- Tacrolimus (TAC), VEL-101
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Veloxis Pharmaceuticals
Cytomegalovirus, Kidney Transplantation
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
This study aims to validate whether Lophius Biosciences Kit T-Track® CMV is suitable to assess the functionality of CMV-specific cell-mediated immunity (CMI) and to determine a protective cut-off value for CMV…
- Conditions
- Cytomegalovirus, Kidney Transplantation, CMV Specific Immune Response
- Trial name
- CMValue (NCT02083042)
- Where
- Germany
- Volunteers
- 97 people
- Sponsor
- Lophius Biosciences GmbH
Renal Failure
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx)
- Trial name
- NCT02051673
- Testing
- Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion
- Where
- United States
- Sponsor
- Talaris Therapeutics Inc.
Kidney Transplantation
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion…
- Trial name
- NCT00170885
- Testing
- Everolimus
- Where
- Switzerland
- Sponsor
- Novartis
Kidney Transplant
A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients
This study is a multicenter, randomized, comparison, open-label, phase IV study in kidney transplant recipients whose immunosuppressive regimen is converted from Cyclosporine with corticosteroid to Advagraf® with corticosteroid.
- Trial name
- COSMOS (NCT02034747)
- Testing
- Advagraf, Corticosteroid
- Where
- 9 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Korea, Inc.
Ischemia-reperfusion Injury, Kidney Transplant; Complications
A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys
Randomized (1:1), placebo controlled, double blind efficacy trial. 200 patients will be followed up for 12 months post transplantation.
- Trial name
- NCT06582485
- Testing
- iCM012 solution 2 mg/mL
- Volunteers
- 200 people
- Sponsor
- iCoat Medical AB